甲基条叶蓟素 | 41365-32-6

• 物质功能分类: 分析化学 - 分析试剂 - 离子色谱试剂
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 甲基条叶蓟素
• 英文名称: cirsilineol
• 英文别名: 3',4',5,6,7-pentahydroxyflavone 3',6,7-trimethyl ether；4',5-dihydroxy-3',6,7-trimethoxyflavone；5,4'-Dihydroxy-6,7,3'-trimethoxyflavone；5,4'-dihydroxy-3',6,7-trimethoxyflavone；5.4'-dihydroxy-6,7,3'-trimethoxyflavone；5,4-dihydroxy-6,7,3'-trimethoxyflavone；Fastigenin；5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxychromen-4-one
• CAS: 41365-32-6
• 化学式: C₁₈H₁₆O₇
• 分子量: 344.321
• InChiKey: VKOSQMWSWLZQPA-UHFFFAOYSA-N

物化性质

• 熔点：
  147 °C(Solv: benzene (71-43-2))
• 沸点：
  585.0±50.0 °C(Predicted)
• 密度：
  1.387
• 溶解度：
  溶于DMSO、乙醇和水；
• LogP：
  1.670 (est)
• 保留指数：
  3343.5

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  94.4
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• WGK Germany：
  3
• 海关编码：
  2914509090
• 储存条件：
  -20°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Cirsilineol
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 41365-32-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 4',5-Dihydroxy-3',6,7-trimethoxyflavone
Anisomelin
6-Methoxyluteolin 3',7-dimethyl ethe
Eupatrin
Fastigenin
Formula : C18H16O7
Molecular Weight : 344,32 g/mol
CAS-No. : 41365-32-6
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white, light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 208 - 210 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,689
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

cirsilinol是一种天然黄酮化合物，能够选择性地抑制肠CD4+T细胞中的IFN-γ/STAT1/T-bet信号。西西林醇具有强大的免疫抑制和抗肿瘤特性，并能显著改善三硝基苯磺酸（TNBS）诱导的小鼠T细胞介导的实验性结肠炎。

反应信息

• 作为反应物：
  描述：

  甲基条叶蓟素 在 双氧水 、 溶剂黄146 、 sodium bromide 作用下， 以64 %的产率得到
  参考文献：
  名称：

  腺苷和牡荆中的新卤代黄酮及其对α-葡萄糖苷酶的抑制作用

  摘要：

  Adenosma bracteosum和Vitex negundo是甲氧基化黄酮类化合物的天然来源。关于多甲氧基化黄酮类衍生物的α-葡萄糖苷酶抑制作用知之甚少。从A. bracteosum和V. negundo中分离得到18 种天然黄酮类化合物。合成了七种卤代衍生物。通过广泛的核磁共振分析和高分辨率质谱以及文献比较阐明了它们的化学结构。评估所有化合物的 α-葡萄糖苷酶抑制作用。大多数化合物表现出良好的活性，IC 50值范围为 16.7 至 421.8 μM。6,8-二溴儿茶素是最活跃的化合物，IC 50值为 16.7 μM。进行的分子对接研究表明这些化合物是有效的 α-葡萄糖苷酶抑制剂。

  DOI：

  10.1002/cbdv.202300390
• 作为产物：
  描述：

  2,3,4-三甲氧基-6-羟基苯乙酮 在 盐酸 、 potassium tert-butylate 、 碘 作用下， 以 乙醇 、 水 、 二甲基亚砜 为溶剂， 生成 甲基条叶蓟素
  参考文献：
  名称：

  Identification and Quantification of Both Methylation and Demethylation Biotransformation Metabolites of 5-Demethylsinensetin in Rats

  摘要：

  DOI：

  10.1021/acs.jafc.1c07509

文献信息

• Characterization of two candidate flavone 8-O-methyltransferases suggests the existence of two potential routes to nevadensin in sweet basil
  作者：Anna Berim、David R. Gang

  DOI：10.1016/j.phytochem.2013.05.001

  日期：2013.8

  recombinant protein was found to be active with a wide range of o-diphenols, and methylated the 8-OH moiety of the flavone backbone with higher catalytic efficiency than the 3'-OH group of candidate substrates. To further investigate flavone 8-O-methylation, the activity of a putative cation-independent flavonoid 8-O-methyltransferase from the same EST collection was assessed with available substrate analogs

  区域选择性 6-,7-,8-,3'- 和 4'-O-甲基化是甜罗勒 (Ocimum basilicum L.) 毛状体中产生的亲脂性黄酮结构多样性的基础。位置 6、7 和 4' 被最近描述的一组不依赖阳离子的酶甲基化。阳离子依赖性 O-甲基转移酶的作用仍需要阐明。在这里，罗勒毛状体 EST 数据库用于识别可能接受类黄酮作为底物的依赖于 Mg(2+) 的 O-甲基转移酶。发现重组蛋白对广泛的邻二酚具有活性，并且以比候选底物的 3'-OH 基团更高的催化效率甲基化黄酮骨架的 8-OH 部分。为了进一步研究黄酮 8-O-甲基化，使用可用的底物类似物评估来自同一 EST 集合的推定的阳离子非依赖性类黄酮 8-O-甲基转移酶的活性。值得注意的是，它被其预期产品之一的栀子 B 强烈抑制。所研究的两种蛋白质的催化能力表明，可能存在两种替代内瓦登辛（一些罗勒栽培品种中的主要黄酮）的途径。将潜在基因的表达与
• NOVEL AIR PURIFICATION COMPOSITION HAVING ANTIVIRAL AND BACTERICIDAL FUNCTIONS
  申请人：Wang, Jingning

  公开号：EP3650105A1

  公开（公告）日：2020-05-13

  Disclosed is a novel air purification composition with antiviral and bactericidal functions, the composition at least comprising the following components in percentage by weight: 0.3%-1% of a black poplar essential oil, 0.1%-1% of a tea tree essential oil, 0.1%-0.5% of a Cupressus funebris essential oil, 0.1%-1% of an Artemisia apiacea essential oil, 0.1%-10% of a Sophora flavescens extract, 0. 1%-5% of a ginger extract, 5%-30% of a Cupressus funebris hydrolate, 0.5%-1% of a hyperbranched amino polymer, 0.5%-5% of a surfactant, and the balance being water.

  本发明公开了一种具有抗病毒和杀菌功能的新型空气净化组合物，该组合物按重量百分比至少包括以下成分：0.3%-1%的黑杨精油、0.1%-1%的茶树精油、0.1%-0.1%-5%的生姜提取物，5%-30%的冲天香水合物，0.5%-1%的超支化氨基酸聚合物，0.5%-5%的表面活性剂，余量为水。
• 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE TREATMENT OF COVID-19
  申请人：ArtemiFlow GmbH

  公开号：EP3884938A1

  公开（公告）日：2021-09-29

  The present invention relates to antiviral 1,2,4-trioxane compounds and compositions comprising the same that are effective inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication, and are thus useful to treat the coronavirus disease 2019 (COVID-19). The invention further provides pharmaceutical compositions containing such antiviral compounds and antiviral compositions, and methods of using these antiviral compounds, antiviral compositions and pharmaceutical compositions in the treatment and prevention of COVID-19.

  本发明涉及抗病毒的1,2,4-三氧杂环己烷化合物和包含这些化合物的组合物，它们是严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）复制的有效抑制剂，因此可用于治疗2019年冠状病毒病（COVID-19）。本发明进一步提供了含有这种抗病毒化合物和抗病毒组合物的药物组合物，以及将这些抗病毒化合物、抗病毒组合物和药物组合物用于治疗和预防COVID-19的方法。
• Glycan therapeutics and related methods thereof
  申请人：KALEIDO BIOSCIENCES, INC.

  公开号：US10314853B2

  公开（公告）日：2019-06-11

  Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

  本发明提供了可选择包含微量营养素、多酚、益生元、益生菌或其他制剂的聚糖疗法制剂、药物组合物及其医用食品，以及制造方法。还提供了使用所述糖治疗剂的方法，例如用于调节人类胃肠道微生物群和治疗菌群失调。
• Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
  申请人：Cedars-Sinai Medical Center

  公开号：US10626180B2

  公开（公告）日：2020-04-21

  The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

  本文公开的方面描述了识别对抗-TNF疗法无反应的受试者的方法。本文公开的方面进一步提供了一种为炎症性肠病（IBD）患者选择疗法并用该疗法治疗该患者的方法。